Peritoneal Fibrosis and High Transport Are Induced in Mildly Pre-injured Peritoneum by 3,4-dideoxyglucosone-3-ene in Mice
Overview
Authors
Affiliations
Peritoneal dialysis (PD) solution contains high concentrations of glucose and glucose degradation products (GDPs). One of several GDPs--3,4-dideoxyglucosone-3-ene (3,4-DGE)--was recently identified as the most reactive and toxic GDP in PD fluids. In vitro, 3,4-DGE has been shown to induce mesothelial cell damage; however, its role in peritoneal fibrosis in vivo remains unclear. In the present study, we intraperitoneally administered chlorhexidine gluconate (CG) for mild peritoneal injury, and we then injected 3,4-DGE [38 μmol/L (low concentration) or 145 μmol/L (high concentration)] 5 times weekly for 4 weeks. Significant thickening of the parietal peritoneal membrane was observed only when treatment with low or high concentrations of 3,4-DGE occurred after CG administration, but not when either CG or 3,4-DGE alone was given. The combination of CG and 3,4-DGE also caused upregulation of messenger RNA expression of transforming growth factor β1, connective tissue growth factor, fibronectin, collagen type 1 α1 chain, alpha smooth muscle actin (α-SMA), vascular endothelial growth factor 164, NADPH oxidase 1 and 4, p22phox, p47phox, and gp91phox in peritoneal tissue. Treatment with CG alone was sufficient to cause significant F4/80-positive macrophage infiltration, appearance of α-SMA-positive cells, and vessel formation in the submesothelial layer. Addition of 3,4-DGE markedly enhanced those changes and induced apoptosis, mainly in leukocytes. The concentration of 3,4-DGE in the abdominal cavity declined more rapidly in CG-treated mice than in PBS-treated mice. Peritoneal membrane permeability determined by peritoneal equilibration test showed high transport conditions in peritoneum treated with both CG and 3,4-DGE. These results indicate that, when mild peritoneal damage is already present, 3,4-DGE causes peritoneal thickening and fibrosis, resulting in deterioration of peritoneal membrane function.
Molecular and Cellular Markers in Chlorhexidine-Induced Peritoneal Fibrosis in Mice.
Brezovec N, Kojc N, Erman A, Hladnik M, Stergar J, Milanic M Biomedicines. 2022; 10(11).
PMID: 36359246 PMC: 9687430. DOI: 10.3390/biomedicines10112726.
Aminoguanidine reduces diabetes-associated cardiac fibrosis.
Magdaleno F, Blajszczak C, Charles-Nino C, Guadron-Llanos A, Vazquez-Alvarez A, Miranda-Diaz A Exp Ther Med. 2019; 18(4):3125-3138.
PMID: 31572553 PMC: 6755450. DOI: 10.3892/etm.2019.7921.
Nano-sized carriers in gene therapy for peritoneal fibrosis .
Igarashi Y, Hoshino T, Ookawara S, Ishibashi K, Morishita Y Nano Rev Exp. 2018; 8(1):1331100.
PMID: 30410706 PMC: 6167028. DOI: 10.1080/20022727.2017.1331100.
Targeting lysyl oxidase reduces peritoneal fibrosis.
Harlow C, Wu X, van Deemter M, Gardiner F, Poland C, Green R PLoS One. 2017; 12(8):e0183013.
PMID: 28800626 PMC: 5553776. DOI: 10.1371/journal.pone.0183013.
Simon F, Tapia P, Armisen R, Echeverria C, Gatica S, Vallejos A Front Physiol. 2017; 8:379.
PMID: 28659813 PMC: 5468383. DOI: 10.3389/fphys.2017.00379.